Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

NCT04804033 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04804033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04804033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Terminated
Start date
March 26, 2021
Completion date
March 21, 2024
Enrollment
1,753 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

migraine